Pharmaresearch Medicare Launches Osteoporosis Treatment 'Teriment Injection'

Teriparatide-Based Treatment
Broader Options for Patients at High Risk of Fractures

Pharmaresearch’s subsidiary, Pharmaresearch Medicare, announced on July 8 that it has launched ‘Teriment Injection’, a teriparatide-based osteoporosis treatment.

Osteoporosis treatment 'Teriment Injection'. Pharmaresearch Medicare

Teriment Injection is a pharmaceutical product used to treat osteoporosis in postmenopausal women and men at high risk of fractures. It can also be prescribed for patients whose risk of fracture has increased due to prolonged use of glucocorticoids.

The main ingredient, teriparatide, is an anabolic agent that promotes osteoblast activity and supports the formation of new bone. Recently, a sequential treatment strategy—administering an anabolic agent first, followed by an antiresorptive agent—has been gaining attention for patients at high risk of fracture, and teriparatide is recognized as a representative substance used in this approach.

Teriment Injection received product approval from the Ministry of Food and Drug Safety in July last year and is a biosimilar to the original product, 'Forsteo Injection'. Through Teriment Injection, Pharmaresearch Medicare aims to expand its musculoskeletal treatment portfolio and stably supply the product to the domestic medical field.

A company representative stated, “With the launch of Teriment Injection, we expect to broaden treatment options for patients at high risk of fractures or in need of rapid bone formation, enabling medical professionals to flexibly utilize treatment options tailored to each patient's condition.”

This content was produced with the assistance of AI translation services.